Scalper1 News
Big biotech Amgen (AMGN) hit a new high in early trading Friday and got several price-target increases from analysts after its strong Q2 and guidance increase late Thursday. Cowen analyst Eric Schmidt raised his price target to 193 from 189 based not only on Thursday’s numbers, but also on the clinical trial data for blood-cancer drug Kyprolis that was used in an FDA filing for an expanded label last week. “In particular, we believe data from ENDEAVOR Scalper1 News
Scalper1 News